Introduction
With ~30000 human genes now discovered, genomics research must turn to unraveling the mechanisms through which those genes create the complexity of life. One of the most obvious challenges includes the elucidations of protein-DNA, protein-RNA, protein-small molecule, and protein-protein interactions, especially in vivo. To understand how these molecules interact with each other, it is crucial to know which protein(s) bind to a specific DNA site, a small molecule, or a protein, in living cells and to measure the level of occupancy of the molecule.
A variety of different in vivo and in vitro technologies provide comprehensive insights concerning protein-ligand interaction networks. Among extensive investigations, one of the most direct ways to study these interactions has been by a crosslinking method using ultraviolet (UV) light or formaldehyde as crosslinking agents in order to covalently attach proteins to their target molecules. 1, 2 Here, a novel crosslinking approach is reported to analyze and to verify protein-ligand interactions by using a highly sensitive detection method of accelerator mass spectrometry (AMS). AMS is a technology for radiocarbon dating, and is now being developed for tracing 14 C-labeled compounds in biological systems. 3, 4 Differently from the conventional liquid scintillation counting method, AMS physically counts radioisotopes, while affording attomole to zeptomole 14 C per mg of total carbon sensitivity with a few percent precision; importantly, the 14 C content in the intact electrophoresis gel can be directly and quantitatively measured by AMS, 5 as is used in the present study.
Experimental

Reagents and procedures
Estrogen receptor-a (ER-a, minimum 80% purity) and [ 14 C]17b-estradiol (E2, 55 mCi/mmol specific activity) were purchased from Sigma-Aldrich (St. Louis, MO) and American Radiolabeled Chemicals, Inc. (St. Louis, MO), respectively. NuPAGE Novex ® Bis-Tris Gel was obtained from Invitrogen (Carlbad, CA). All other chemicals used in this study were of the highest grade available, and were used without further purification.
To obtain radiocarbon-labeled crosslinked complexes, 21.4 pmol of ER-a (214 nM final concentration) in a binding buffer 6 (40 mM Tris-HCl, pH 7.4, 1 mM EDTA, 10% (v/v) glycerol, 10 mM Na2MoO4, 10 mM DTT) was incubated with 2.1 fmol of E2 containing 0.91 fmol of [ 14 C]E2 at 4˚C for 16 h, followed by adding formaldehyde (0.09% w/v final concentration) to the solution in order to make the protein-ligand complex covalently linked. After incubation with occasional mixing at room temperature for 15 min, the reaction was quenched by a lysine solution (125 mM final concentration), and the resulting mixture was subjected to gel electrophoresis (GE) separation according the manufacturer's manual. After the gel was stained with a Bio-Rad Coomassie ® Stain Solution and a picture was taken, the gel was cut into 0.8 ¥ 0.4 cm 2 size, and then dried. The resulting gels were converted to solid carbon for AMS measurements using a two-step process, according to the literature. 5 Briefly, the sliced gels in quartz combustion tubes were oxidized to CO2 using excess copper oxide, and the evolved CO2 was reduced to graphite by both reduction with titanium hydride and zinc powder and catalyzation with iron. Large C samples (>500 mg) were split and the 12 C: 14 C ratios were measured by stable isotope ratio mass spectrometry. Graphite targets were measured at the Center for Accelerator Mass Spectrometry at Lawrence Livermore National Laboratory.
Results and Discussion
[ 14 C]E2 and ER-a were chosen in this study because of the high binding affinity (~0.2 nM) and the well-characterized biochemistry, [6] [7] [8] A highly sensitive detection method for the determination of protein-ligand interactions has been developed. Radiocarbon-labeled 17b-estradiol was incubated with estrogen receptor-a as a selective binding partner, and covalently attached using crosslinking agents, to form covalently linked protein-ligand complexes. After separation using a denaturing gel, the 14 C content in the sliced gels was identified by accelerator mass spectrometry. The obtained data demonstrated specific binding of the small molecule to its binding partner. In theory, this method can be applied to most protein-ligand interaction studies. the hydroxy groups could subsequently react with the crosslinking agent, formaldehyde in this study, resulting in covalently linked complex formation (Fig. 1) .
After following the experimental procedures described above as well as in Fig. 2 (caption) , each sliced gel was measured by AMS. Figure 2 shows that only the sliced gel Number 2 resulted in a significant AMS signal with a high signal-to-noise, compared with the background levels of radioactivities in other sliced gels. The measured level of radiocarbon in the sliced gel Number 2 corresponds to approximately 83% of the total radiocarbon used, based on an assumption that the weight of each sliced gel was 3.5 mg. Since a denaturing gel was employed for GE, these data indicate that covalently linked protein-ligand complexes were formed.
To support this conclusion, a control experiment was performed under identical conditions, except for the formaldehyde treatment (lane F in Fig. 2) . No radiocarbon was observed in the sliced gels (Fig. 2b,  right) , suggesting that no [ 14 C]E2 was covalently attached to ER-a in the absence of formaldehyde. Interestingly, ER-a treated with formaldehyde seems to have a slightly higher molecular weight (i.e. lower mobility, lane D in Fig. 2a ) compared with the ER-a standard without any treatment (lane C in Fig. 2a) . Furthermore, an AMS measurement was found to overcome the detection limit of the Importantly, the AMS-based assay method reported here could discriminate the specific binding between ER-a and E2 from non-specific binding. Partially purified ER-a (80% purity guaranteed by the manufacturer, see lane B in Fig. 2a ) was used, but the AMS signal in this study resulted only from the sliced gel, which was expected to contain covalently linked ER-a-E2 complexes. This approach is obviously different from the previous AMS studies found in the literature, 5 which have focused on non-specific chemical reactions of several carcinogens. Moreover, much lower background levels of radiocarbon were observed, representing the power of this approach for specific binding studies.
The present study of protein-small molecule interactions using a radiolabeled probe suggests that the AMS-based crosslinking method can generally be applied to other identification studies of (novel) target proteins in protein-DNA, -RNA, -small molecule, or -protein interactions both in vitro and in vivo. This is because: i) radiolabeled nucleotides can be inserted in a DNA sequence of a plasmid using conventional oligonucleotide synthetic methods, followed by DNA shuffling methods, ii) a radiolabeled small molecule, such as a drug, a hormone, or a metabolite, can be introduced in a biological system, and iii) a radiolabeled photoactive linker can be specifically introduced to a protein of interest. 1, [9] [10] [11] [12] Though it is not yet optimized to quantify the amount of radiolabeled molecule in a gel due to a difficulty arising from the hard-to-measure amount of total carbons in the sliced gel (AMS measures only 14 C: 13 C or 14 C: 12 C ratios depending on the instrument setup, that is to say, it is critical to precisely quantify 13 C or 12 C in a gel prior to 14 C quantitation), this study strongly proposes that the developed AMS method can at least qualitatively answer whether the ligand of interest binds to given specific proteins. An alternative to a direct measurement of radioactivity from a gel would be to use a protein extraction kit from a gel (BioRAD) in order to quantify and identify novel binding/repair proteins.
Conclusions
Overall, the obtained data demonstrate that protein-ligand interactions can be specifically detected by AMS with high sensitivity. The demonstrated capability of AMS in the present study, in combination with previous AMS methods development to measure actual amounts of DNA adducts in cultured cells and in vivo, and with the availability of well-characterized biochemistry, is expected to set the stage for the identification of known or novel proteins as binding partners, which may lead to drug development in the future. 
